Abstract

Review Article

Systematic review and meta-analysis of drug induced liver injury secondary to biologic medications in inflammatory bowel disease

Eyad Gadour* and Zeinab Hassan

Published: 01 February, 2021 | Volume 5 - Issue 1 | Pages: 005-012

Drug-induced Hepatotoxicity and biologic drugs have historically been challenging in IBD. We aim to study the prevalence of hepatotoxicity in adult patients using biologic medications.

Read Full Article HTML DOI: 10.29328/journal.acgh.1001025 Cite this Article Read Full Article PDF

References

  1. Feagan B, Sandborn WJ, Rutgeerts P, Levesque BG, Khanna R, et al. Performance of Crohn's disease Clinical Trial Endpoints based upon Different Cutoffs for Patient Reported Outcomes or Endoscopic Activity: Analysis of EXTEND Data. Inflamm Bowel Dis. 2018; 24: 932-942. PubMed: https://pubmed.ncbi.nlm.nih.gov/29668919/
  2. Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011; 141: 1194-1201. PubMed: https://pubmed.ncbi.nlm.nih.gov/21723220/
  3. Szamosi T, Banai J, Lakatos L, Czegledi Z, David G, et al. Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn's disease, while smoking decreases the risk of colectomy in ulcerative colitis. Eur J Gastroenterol Hepatol. 2010; 22: 872-879. PubMed: https://pubmed.ncbi.nlm.nih.gov/19648821/
  4. Wilhelm SM, McKenney KA, Rivait KN, Kale-Pradhan PB. A review of infliximab use in ulcerative colitis. Clin Ther. 2008; 30: 223-230. PubMed: https://pubmed.ncbi.nlm.nih.gov/18343261/
  5. Vatn MH. Mucosal healing: impact on the natural course or therapeutic strategies. Dig Dis. 2009; 27: 470-475. PubMed: https://pubmed.ncbi.nlm.nih.gov/19897962/
  6. Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006; 63: 433-442. PubMed: https://pubmed.ncbi.nlm.nih.gov/16500392/
  7. Burisch J. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort. Dan Med J. 2014; 61: B4778. PubMed: https://pubmed.ncbi.nlm.nih.gov/24393595/
  8. Fratila OC, Craciun C. Ultrastructural evidence of mucosal healing after infliximab in patients with ulcerative colitis. J Gastrointestin Liver Dis. 2010; 19: 147-153. PubMed: https://pubmed.ncbi.nlm.nih.gov/20593047/
  9. Romberg-Camps MJ, Dagnelie PC, Kester AD, Hesselink-van de Kruijs MAM, Cilissen M, et al. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol. 2009; 104: 371-383. PubMed: https://pubmed.ncbi.nlm.nih.gov/19174787/
  10. Henriksen M, Jahnsen J, Lygren I, Aadland E, Schulz T, et al. Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study). Scand J Gastroenterol. 2007; 42: 602-610. PubMed: https://pubmed.ncbi.nlm.nih.gov/17454881/
  11. Van Assche G. Does mucosal healing impact patient outcomes long-term? Inflamm Bowel Dis. 2008; 14: 577-578. PubMed: https://pubmed.ncbi.nlm.nih.gov/18240284/
  12. Khanna R, Zou G, D'Haens G, Sandborn WJ, Vandervoort MK, et al. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity. Aliment Pharmacol Ther. 2015; 41: 77-86. PubMed: https://pubmed.ncbi.nlm.nih.gov/25348809/
  13. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010; 59: 49-54. PubMed: https://pubmed.ncbi.nlm.nih.gov/19651627/
  14. Scheinfeld N. Adalimumab: a review of side effects. Expert Opin Drug Saf. 2005; 4: 637-641. PubMed: https://pubmed.ncbi.nlm.nih.gov/16011443/
  15. Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015; 148: 1320-1329. PubMed: https://pubmed.ncbi.nlm.nih.gov/25724455/
  16. Ben-Horin S. Drug Level-based Anti-Tumor Necrosis Factor Therapy: Ready for Prime Time? Gastroenterology. 2015; 148: 1268-1271. PubMed: https://pubmed.ncbi.nlm.nih.gov/25921372/
  17. Chanson P, Pariente A. [Adapting the dose to the residual concentration of infliximab in cryptogenic inflammatory diseases of the intestines]. Rev Prat. 2015; 65: 473.
  18. Orfanoudaki E, Gazouli M, Foteinogiannopoulou K, et al. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab. Eur J Gastroenterol Hepatol. 2019; 31: 187-191. PubMed: https://pubmed.ncbi.nlm.nih.gov/30543573/
  19. Beppu T, Ono Y, Matsui T, Hirai F, Yano Y, et al. Mucosal healing of ileal lesions is associated with long-term clinical remission after infliximab maintenance treatment in patients with Crohn's disease. Dig Endosc. 2015; 27: 73-81. PubMed: https://pubmed.ncbi.nlm.nih.gov/24833527/
  20. Shah P, Sundaram V, Björnsson E. Biologic and Checkpoint Inhibitor‐Induced Liver Injury: A Systematic Literature Review. Hepatol Commun. 2020; 4: 172–184. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996412/
  21. Peyrin-Biroulet L, Ferrante M, Magro F, Campbell S, Franchimont D, et al. Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis. 2011; 5: 477-483. PubMed: https://pubmed.ncbi.nlm.nih.gov/21939925/
  22. Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis. 2010; 16: 1598-1619. PubMed: https://pubmed.ncbi.nlm.nih.gov/20198712/
  23. Raj V, Lichtenstein DR. Hepatobiliary manifestations of inflammatory bowel disease. Gastroenterol Clin North Am. 1999; 28: 491-513. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10372279
  24. Rojas-Feria M, Castro M, Suárez E, Ampuero J, Romero-Gómez M. Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver. World J Gastroenterol. 2013; 19: 7327-7340. PubMed: https://pubmed.ncbi.nlm.nih.gov/24259964/
  25. Lichtenstein DR. Hepatobiliary complications of inflammatory bowel disease. Curr Gastroenterol Rep. 2011; 13: 495-505. PubMed: https://pubmed.ncbi.nlm.nih.gov/21773706/
  26. Jiang Y, Lin O, Sinha SR. Use of Tumor Necrosis Factor Alpha Inhibitors for Inflammatory Bowel Disease Patients with Concurrent Heart Failure. Dig Dis Sci. 2017; 62: 1597-1606. PubMed: https://pubmed.ncbi.nlm.nih.gov/28417241/
  27. Magro F, Portela F. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. BioDrugs. 2010; 24 Suppl1: 3-14. PubMed: https://pubmed.ncbi.nlm.nih.gov/21175228/
  28. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6: e1000097. PubMed: https://pubmed.ncbi.nlm.nih.gov/19621072/
  29. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 2009; 3: e123-130.
  30. Higgins JP AD, Sterne JA. Chapter 8: Assessing, risk of bias in included studies. In: Higgins JP CR, Chandler J CM, editor(s). Cochrane Handbook for, (updated SRoIv, June 2017). The Cochrane Collaboration Af. www.training.cochrane.org/handbook.
  31. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343: d5928. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3196245/
  32. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315: 629-634. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2127453/
  33. Bastida G, Nos P, Aguas M, Beltrán B, Rubín A, et al. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005; 22: 775-782. PubMed: https://pubmed.ncbi.nlm.nih.gov/16225485/
  34. Koller T, Galambosova M, Filakovska S, Kubincova M, Hlavaty T, et al. Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study. World J Gastroenterol. 2017; 23: 4102–4111. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473129/
  35. Paul S, Del Tedesco E, Marotte H, Rinaudo-Gaujous M, Moreau A, et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2013; 19: 2568-2576. PubMed: https://pubmed.ncbi.nlm.nih.gov/24013361/
  36. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis. 2009; 15: 1295-1301. PubMed: https://pubmed.ncbi.nlm.nih.gov/19340881/
  37. Bertani L, Bodini G, Mondello G, Mumolo MG. Crohn’s disease patients treated with anti-TNF: a prospective multi-centre study. 2019; 13(Supplement_1):S402-S403.
  38. Tighe D, Hall B, Jeyarajah SK, Smith S, Breslin N, et al. One-Year Clinical Outcomes in an IBD Cohort Who Have Previously Had Anti-TNFa Trough and Antibody Levels Assessed. Inflamm Bowel Dis. 2017; 23: 1154-1159. PubMed: https://pubmed.ncbi.nlm.nih.gov/28486256/
  39. Warman A, Straathof JW, Derijks LJ. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study. Eur J Gastroenterol Hepatol. 2015; 27: 242-248. PubMed: https://pubmed.ncbi.nlm.nih.gov/25569569/
  40. Koller T, Galambosova M, Filakovska S, Kubincova M, Hlavaty T, et al. Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study. World J Gastroenterol. 2017; 23: 4102-4111. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473129/
  41. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 2462-2476. PubMed: https://pubmed.ncbi.nlm.nih.gov/16339095/
  42. Goldstein ES, Marion JF, Present DH. 6-Mercaptopurine is effective in Crohn's disease without concomitant steroids. Inflamm Bowel Dis. 2004; 10: 79-84. PubMed: https://pubmed.ncbi.nlm.nih.gov/15168805/
  43. de Jong DJ, Goullet M, Naber TH. Side effects of azathioprine in patients with Crohn's disease. Eur J Gastroenterol Hepatol. 2004; 16: 207-212. PubMed: https://pubmed.ncbi.nlm.nih.gov/15075996/
  44. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis. 2002; 22: 145-155. PubMed: https://pubmed.ncbi.nlm.nih.gov/12016546/
  45. Larrey D. Drug-induced liver diseases. J Hepatol. 2000; 32(1 Suppl): 77-88. PubMed: https://pubmed.ncbi.nlm.nih.gov/10728796/
  46. Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006; 4: 1248-1254. PubMed: https://pubmed.ncbi.nlm.nih.gov/16931170/
  47. Rutgeerts P, Vermeire S, Van Assche G. Predicting the response to infliximab from trough serum levels. Gut. 2010; 59: 7-8. PubMed: https://pubmed.ncbi.nlm.nih.gov/20007955/
  48. Ben-Horin S, Yavzori M, Katz L, et al. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut. 2011; 60: 41-48. PubMed: https://pubmed.ncbi.nlm.nih.gov/20519742/
  49. Boschetti G, Garnero P, Moussata D, et al. Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's disease. Inflamm Bowel Dis. 2015; 21: 331-336. PubMed: https://pubmed.ncbi.nlm.nih.gov/25625487/
  50. Menor C, Fernández-Moreno MD, Fueyo JA, et al. Azathioprine acts upon rat hepatocyte mitochondria and stress-activated protein kinases leading to necrosis: protective role of N-acetyl-L-cysteine. J Pharmacol Exp Ther. 2004; 311: 668-676. PubMed: https://pubmed.ncbi.nlm.nih.gov/15226385/
  51. Tapner MJ, Jones BE, Wu WM, Farrell GC. Toxicity of low dose azathioprine and 6-mercaptopurine in rat hepatocytes. Roles of xanthine oxidase and mitochondrial injury. J Hepatol. 2004; 40: 454-463. PubMed: https://pubmed.ncbi.nlm.nih.gov/15123360/
  52. Choudhury J, Sanyal AJ. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis. 2004; 8: 575-594. PubMed: https://pubmed.ncbi.nlm.nih.gov/15331065/
  53. Farrell GC. Drugs and steatohepatitis. Semin Liver Dis. 2002; 22: 185-194. PubMed: https://pubmed.ncbi.nlm.nih.gov/12016549/
  54. Morris JM, Oien KA, McMahon M, Forrest EH, Morris J, et al. Nodular regenerative hyperplasia of the liver: survival and associated features in a UK case series. Eur J Gastroenterol Hepatol. 2010; 22: 1001-1005. PubMed: https://pubmed.ncbi.nlm.nih.gov/20075739/
  55. Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990; 11: 272-276. PubMed: https://pubmed.ncbi.nlm.nih.gov/2254635/
  56. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989; 170: 2-6. PubMed: https://pubmed.ncbi.nlm.nih.gov/2617184/
  57. Weersma RK, Peters FT, Oostenbrug LE, van den Berg AP, van Haastert M, et al. Increased incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases. Aliment Pharmacol Ther. 2004; 20: 843-850. PubMed: https://pubmed.ncbi.nlm.nih.gov/15479355/
  58. Marion JF. Toxicity of 6-mercaptopurine/azathioprine in patients with inflammatory bowel disease. Inflamm Bowel Dis. 1998; 4: 116-117. PubMed: https://pubmed.ncbi.nlm.nih.gov/9687219/
  59. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989; 111: 641-649. PubMed: https://pubmed.ncbi.nlm.nih.gov/2802419/
  60. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut. 2009; 58: 492-500. PubMed: https://pubmed.ncbi.nlm.nih.gov/18832518/
  61. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362: 1383-1395. PubMed: https://pubmed.ncbi.nlm.nih.gov/20393175/
  62. Roblin X, Marotte H, Leclerc M, Del Tedesco E, Phelip JM, et al. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease. J Crohns Colitis. 2015; 9: 525-531. PubMed: https://pubmed.ncbi.nlm.nih.gov/25895875/
  63. Imaeda H, Bamba S, Takahashi K, Fujimoto T, Ban H, et al. Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment. J Gastroenterol. 2014; 49: 674-682. PubMed: https://pubmed.ncbi.nlm.nih.gov/23666424/
  64. Frøslie KF, Jahnsen J, Moum BA, Vatn MH. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007; 133: 412-422. PubMed: https://pubmed.ncbi.nlm.nih.gov/17681162/

Figures:

Figure 1

Figure 1

Figure 1

Figure 2

Figure 1

Figure 3

Figure 1

Figure 4

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More